Torrent Pharmaceuticals Ltd, one of India’s leading drug manufacturers, has taken a major step to strengthen its financial position. The company’s board has approved a plan to raise up to ₹12,500 crore through the issuance of bonds, also known as Non-Convertible Debentures (NCDs).
According to the company’s regulatory filing, the fund-raising will be done through private placement, and the bonds may be issued in one or multiple tranches. The NCDs will be listed on the NSE’s Wholesale Debt Market segment.
Key Details of the Bond Issue
Torrent Pharma stated that the approval was granted by its Securities Transfer and Stakeholders Relationship Committee. The proposed bonds will be:
- Secured
- Rated
- Listed
- Non-convertible (cannot be converted into equity shares)
The company added that important terms such as interest rate, tenure, and maturity date will be decided at the time of issuance, depending on market conditions.
Why Is Torrent Pharma Raising ₹12,500 Crore?
Market experts believe the large fund-raising plan is driven by Torrent Pharma’s long-term growth strategy.
1. Funding Major Acquisition Plans
Torrent Pharma is in the process of acquiring JB Chemicals & Pharmaceuticals, a deal estimated at around ₹19,500 crore. The bond issue is expected to play a key role in financing this acquisition.
2. Business Expansion and Growth
The company plans to use the funds to support:
- Research and development (R&D)
- New product launches
- Expansion in domestic and international markets
3. Strengthening Financial Flexibility
By raising funds through bonds, Torrent Pharma aims to maintain healthy cash flows and ensure financial flexibility for future opportunities.
About Torrent Pharmaceuticals
Torrent Pharmaceuticals is a well-established Indian pharmaceutical company with a strong presence in branded formulations.
- Headquarters: Ahmedabad, Gujarat
- Global Presence: Operations in over 50 countries
- Core Focus Areas: Cardiovascular, diabetes, neurology, gastroenterology
- Manufacturing Base: Eight manufacturing facilities, including USFDA-approved plants
The company derives a large portion of its revenue from chronic and sub-chronic therapies, which provide stable and recurring income.
Financial Position Remains Strong
Recent financial performance indicates that Torrent Pharma is well-placed to handle additional debt.
- Revenue has shown double-digit growth
- EBITDA margins remain strong
- Net debt to EBITDA ratio is within comfortable limits
Credit rating agencies have reaffirmed the company’s AA+ rating, reflecting strong credit quality and repayment capability.
What Does This Mean for Investors?
Positive Factors
- Clear long-term growth strategy
- Support for large acquisitions and expansion plans
- Strong balance sheet and credit profile
Risks to Watch
- Higher debt could increase interest costs
- Integration challenges related to acquisitions
Simple Explanation
In simple terms, Torrent Pharma has received board approval to raise up to ₹12,500 crore through bonds to fund its future growth and acquisition plans. Given the company’s strong financial position, the move is being seen as a strategic and well-planned decision by market participants.
Source: bseindia
